Clin2
NCT07318948Likely a fitNot yet recruiting

Blood pressure control in stroke patients receiving thrombolysis

Acute Ischemic Stroke

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests a strategy for managing high blood pressure in people having an acute ischemic stroke who are about to receive clot-busting medication. It aims to see if carefully lowering blood pressure within a specific range improves outcomes.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
1,600 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You are having an acute ischemic stroke (a clot blocking blood flow in the brain) and the start of symptoms or last known well time is within 4.5 hours.
  • Your doctor has decided to treat you with intravenous clot-busting medication (thrombolysis).
  • Your blood pressure is higher than the recommended range for thrombolysis (for example, above 180/110 in some regions) but below 220 mmHg, confirmed by two separate readings.
  • You or a legally authorized representative can give consent (or a deferred consent process is allowed).
  • You are not pregnant or breastfeeding, and you are not enrolled in another trial that could interfere with this study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07279259Recruiting· Phase 2
Blood pressure management after stroke clot-dissolving treatment

This trial tests how managing high blood pressure during clot-dissolving treatment for acute ischemic stroke affects recovery. It is for patients who have high blood pressure at the start of treatment.

Shanghai
NCT06677970Recruiting· Phase 3
Blood Pressure Control After Stroke Thrombectomy

This trial tests whether carefully lowering blood pressure after a mechanical clot removal procedure for stroke can improve outcomes. If you've had a large vessel stroke that was successfully treated with thrombectomy, this study will help guide blood pressure management in the recovery period.

Seoul, Seoul
NCT07137832Recruiting· Phase 3
Testing clot-busting drug during stroke treatment for medium vessel blockages

This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.

Guangzhou, Guangdong
NCT07537933Not yet recruiting· Phase 3
Blood Thinner Injection During Stroke Clot Removal

This trial tests whether injecting a blood thinner called tirofiban directly into brain blood vessels during a stroke procedure helps prevent clots from forming again. If you've had a stroke caused by a large clot in your brain that was successfully removed, this study may help protect your recovery.

Jinan, Shandong
NCT07621796Not yet recruiting· Phase 3
Tenecteplase for Stroke Patients Taking Blood Thinners

This trial tests whether a clot-busting drug called tenecteplase works safely in people having a stroke who are already taking certain blood-thinning medications (like apixaban or rivaroxaban). The goal is to see if it can restore blood flow to the brain better than current treatments.

Neptune City, New Jersey
NCT06749834Recruiting· Phase 3
Clot-busting drug after stroke in people on newer blood thinners

This trial tests whether a clot-busting medication given through a vein (intravenous thrombolysis) can safely treat acute ischemic stroke within 24 hours in people who have taken a newer oral blood thinner (NOAC) within the last 4 to 48 hours.

Hangzhou, Zhejiang

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.